Extended Data Fig. 2: Bumetanide treatment does not affect swim speed or visible trial performance in aged apoE4-KI mice and does not affect behavioral performance in wildtype (WT) mice.
a, Bumetanide did not significantly affect swim speed during hidden platform trials of apoE4-KI and apoE3-KI mice (n = 11 for each group) at 24 month of age over learning days 1–5. b, There was no significant difference between any groups in visible trials (measured by 2-way ANOVA) of apoE4-KI and apoE3-KI mice (n = 11 for each group), indicating there were no motor or vision impairment in any of the groups. c, Escape latency of vehicle (n = 16) and bumetanide (n = 15) treated WT mice during learning days 1–5 did not differ. d, Bumetanide did not significantly affect swim speed during hidden platform trials in WT mice (n = 15) as compared to vehicle treated WT controls (n = 16). e, In the 24-hour probe trial, both vehicle (n = 16, two way ANOVA with Bonferroni’s multiple comparisons test P < 0.0001) and bumetanide (n = 15, two way ANOVA with Bonferroni’s multiple comparisons test P = 0.0001) treated WT mice spent significantly more time in the target quadrant versus average percent time in the other quadrants. f, In the 72-hour probe trial, both vehicle (n = 16, two way ANOVA with Bonferroni’s multiple comparisons test P = 0.0054) and bumetanide (n = 15, two way ANOVA with Bonferroni’s multiple comparisons test P < 0.0001) treated WT mice spent more time in the target quadrant than the other quadrants. Values are mean ± SEM in a-f.
